IOVANCE BIOTHERAPEUTICS, INC. (IOVA) Scorecard
- 2026-Q2: Total return Win; Revenue growth Win; EPS growth No data.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth No data.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth No data.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth No data.
27/60
2.3 / 5 stars
All 60 Win/Lose results and 60 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 8 wins, 0 losses, 4 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/2 |
WinIOVA / S&P 18.52% / 15.20% |
WinIOVA / S&P 34.55% / 15.00% |
No dataIOVA / S&P / 50.40% |
| 2026-Q12/2 |
WinIOVA / S&P 28.57% / -4.33% |
WinIOVA / S&P 34.29% / 11.30% |
No dataIOVA / S&P / 27.70% |
| 2025-Q42/2 |
WinIOVA / S&P 25.81% / 2.65% |
WinIOVA / S&P 60.60% / 9.00% |
No dataIOVA / S&P / 13.40% |
| 2025-Q32/2 |
WinIOVA / S&P 26.16% / 8.12% |
WinIOVA / S&P 175.62% / 4.61% |
No dataIOVA / S&P / 13.45% |
| 2025-Q21/3 |
LoseIOVA / S&P -48.35% / 10.94% |
WinIOVA / S&P 636.99% / 4.83% |
LoseIOVA / S&P -26.95% / 10.63% |
| 2025-Q11/3 |
LoseIOVA / S&P -55.00% / -4.27% |
WinIOVA / S&P 11070.12% / 4.98% |
LoseIOVA / S&P -31.67% / 10.57% |
| 2024-Q40/2 |
LoseIOVA / S&P -21.19% / 2.41% |
No dataIOVA / S&P / 5.25% |
LoseIOVA / S&P -31.38% / 6.15% |
| 2024-Q31/2 |
WinIOVA / S&P 17.08% / 5.89% |
No dataIOVA / S&P / 5.89% |
LoseIOVA / S&P -28.02% / 6.11% |
| 2024-Q20/2 |
LoseIOVA / S&P -45.88% / 4.28% |
No dataIOVA / S&P / 5.38% |
LoseIOVA / S&P -25.45% / 5.12% |
| 2024-Q11/2 |
WinIOVA / S&P 82.29% / 10.56% |
No dataIOVA / S&P / 5.71% |
LoseIOVA / S&P -25.00% / 5.59% |
| 2023-Q41/2 |
WinIOVA / S&P 78.68% / 11.69% |
No dataIOVA / S&P / 6.81% |
LoseIOVA / S&P -24.19% / 7.78% |
| 2023-Q30/2 |
LoseIOVA / S&P -35.37% / -3.27% |
No dataIOVA / S&P / 7.52% |
LoseIOVA / S&P -16.19% / -5.03% |
| 2023-Q22/2 |
WinIOVA / S&P 15.22% / 8.74% |
No dataIOVA / S&P / 9.50% |
WinIOVA / S&P -6.28% / -8.57% |
| 2023-Q11/2 |
LoseIOVA / S&P -4.38% / 7.50% |
No dataIOVA / S&P / 10.77% |
WinIOVA / S&P 4.80% / -15.69% |
| 2022-Q41/2 |
LoseIOVA / S&P -33.30% / 7.56% |
No dataIOVA / S&P / 11.88% |
WinIOVA / S&P 11.71% / -17.99% |
| 2022-Q31/2 |
LoseIOVA / S&P -13.22% / -4.88% |
No dataIOVA / S&P / 13.47% |
WinIOVA / S&P 19.90% / -1.41% |
| 2022-Q21/2 |
LoseIOVA / S&P -33.69% / -16.10% |
No dataIOVA / S&P / 13.71% |
WinIOVA / S&P 25.13% / 11.04% |
| 2022-Q10/2 |
LoseIOVA / S&P -12.78% / -4.60% |
No dataIOVA / S&P / 15.97% |
LoseIOVA / S&P 23.78% / 42.23% |
| 2021-Q40/1 |
LoseIOVA / S&P -22.59% / 11.03% |
No dataIOVA / S&P / 15.00% |
No dataIOVA / S&P / 96.40% |
| 2021-Q30/1 |
LoseIOVA / S&P -5.23% / 0.58% |
No dataIOVA / S&P / 10.77% |
No dataIOVA / S&P / 69.42% |
| 2021-Q20/1 |
LoseIOVA / S&P -17.81% / 8.55% |
No dataIOVA / S&P / 6.58% |
No dataIOVA / S&P / 51.81% |
| 2021-Q10/1 |
LoseIOVA / S&P -31.77% / 6.17% |
No dataIOVA / S&P / -1.06% |
No dataIOVA / S&P / 7.39% |
| 2020-Q41/1 |
WinIOVA / S&P 40.95% / 12.15% |
No dataIOVA / S&P / -3.72% |
No dataIOVA / S&P / -33.42% |
| 2020-Q31/1 |
WinIOVA / S&P 19.93% / 8.93% |
No dataIOVA / S&P / -2.04% |
No dataIOVA / S&P / -27.10% |
| 2020-Q20/1 |
LoseIOVA / S&P -8.32% / 20.54% |
No dataIOVA / S&P / -0.46% |
No dataIOVA / S&P / -27.11% |
| 2020-Q11/1 |
WinIOVA / S&P 8.16% / -19.60% |
No dataIOVA / S&P / 3.47% |
No dataIOVA / S&P / -14.75% |
| 2019-Q41/1 |
WinIOVA / S&P 52.09% / 9.07% |
No dataIOVA / S&P / 5.36% |
No dataIOVA / S&P / 2.99% |
| 2019-Q30/1 |
LoseIOVA / S&P -25.77% / 1.70% |
No dataIOVA / S&P / 5.02% |
No dataIOVA / S&P / 0.21% |
| 2019-Q21/1 |
WinIOVA / S&P 157.83% / 4.30% |
No dataIOVA / S&P / 6.64% |
No dataIOVA / S&P / 8.65% |
| 2019-Q10/1 |
LoseIOVA / S&P 7.46% / 13.65% |
No dataIOVA / S&P / 8.12% |
No dataIOVA / S&P / 14.29% |
| 2018-Q40/1 |
LoseIOVA / S&P -21.33% / -13.52% |
No dataIOVA / S&P / 9.05% |
No dataIOVA / S&P / 18.23% |
| 2018-Q30/1 |
LoseIOVA / S&P -12.11% / 7.71% |
No dataIOVA / S&P / 10.21% |
No dataIOVA / S&P / 19.06% |
| 2018-Q20/1 |
LoseIOVA / S&P -24.26% / 3.43% |
No dataIOVA / S&P / 9.03% |
No dataIOVA / S&P / 14.46% |
| 2018-Q11/1 |
WinIOVA / S&P 111.25% / -0.76% |
No dataIOVA / S&P / 7.68% |
No dataIOVA / S&P / 12.46% |
| 2017-Q40/1 |
LoseIOVA / S&P 3.23% / 6.64% |
No dataIOVA / S&P / 7.03% |
No dataIOVA / S&P / 13.82% |
| 2017-Q31/1 |
WinIOVA / S&P 5.44% / 4.48% |
No dataIOVA / S&P / 5.68% |
No dataIOVA / S&P / 17.57% |
| 2017-Q20/1 |
LoseIOVA / S&P -1.34% / 3.09% |
No dataIOVA / S&P / 4.83% |
No dataIOVA / S&P / 17.74% |
| 2017-Q11/1 |
WinIOVA / S&P 7.19% / 6.07% |
No dataIOVA / S&P / 3.67% |
No dataIOVA / S&P / 13.32% |
| 2016-Q40/1 |
LoseIOVA / S&P -15.55% / 3.82% |
No dataIOVA / S&P / 2.09% |
No dataIOVA / S&P / 7.05% |
| 2016-Q30/1 |
LoseIOVA / S&P 1.60% / 3.85% |
No dataIOVA / S&P / 0.20% |
No dataIOVA / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | IOVA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 270.40% | 20.78% |
| Annualized return | 270.40% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | IOVA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -66.02% | 83.14% |
| Annualized return | -19.42% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | IOVA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 3.64% | 319.30% |
| Annualized return | 0.36% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |